RT期刊文章SR电子T1疗效和安全性的吸入α1-antitrypsin患者严重α1-antitrypsin不足和频繁的慢性阻塞性肺病加重病人的摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1900673 10.1183/13993003.00673 -2019签证官54是5 A1 Stolk, Jan A1 Tov Naveh A1查普曼,188bet官网地址Kenneth R. A1 Fernandez, Pablo A1 MacNee, William A1 Hopkinson, Nicholas S. A1 Piitulainen, Eeva A1 Seersholm, Niels A1 Vogelmeier, Claus F. A1 Bals, Robert A1 McElvaney, Gerry A1 Stockley，慢性阻塞性肺疾病(COPD)是一种严重的慢性阻塞性肺疾病。我们假设吸入雾化AAT是一种有效的治疗方法。我们随机分配168例患者接受每日两次吸入80mg AAT溶液或安慰剂50周。患者使用电子日记记录病情恶化情况。主要终点是从随机分组到第一次以事件为基础的病情恶化的时间。次要终点包括Anthonisen标准定义的恶化性质的改变。安全性也得到了评估。首次中度或重度发作的时间中位数为AAT为112天(四分位数区间(IQR) 40-211天)，安慰剂为140天(IQR 72-142天)(p=0.0952)。 The mean yearly rate of all exacerbations was 3.12 in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.We conclude that in AATD patients with severe COPD and frequent exacerbations, AAT inhalation for 50 weeks showed no effect on time to first exacerbation but may have changed the pattern of the episodes.Inhaled α1-antitrypsin did not significantly reduce the time to first exacerbation in patients with severe α1-antitrypsin deficiency who experience frequent exacerbations of COPD in a randomised placebo-controlled clinical trial of 1 year http://bit.ly/2P5zXdK